Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University College, London
AstraZeneca
Takeda
Fondazione Italiana Linfomi - ETS
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
University College, London
University of New Mexico
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Gustave Roussy, Cancer Campus, Grand Paris
Fondazione Michelangelo
UNICANCER
Radiation Therapy Oncology Group
Canadian Cancer Trials Group
University of Cologne
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
SWOG Cancer Research Network
SWOG Cancer Research Network
European Organisation for Research and Treatment of Cancer - EORTC
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Fondazione Michelangelo
Radiation Therapy Oncology Group
SWOG Cancer Research Network
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gustave Roussy, Cancer Campus, Grand Paris
SWOG Cancer Research Network
European Organisation for Research and Treatment of Cancer - EORTC
M.D. Anderson Cancer Center
American Scitech International
Fondazione Italiana Linfomi - ETS